Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tamsulosin is a selective alpha-1A and alpha-1B adrenergic receptor antagonist primarily used to treat the symptoms of benign prostatic hyperplasia (BPH), such as difficulty urinating and urinary frequency in men[2][3][5]. By selectively blocking alpha-1A adrenergic receptors in the smooth muscle of the prostate and bladder neck—where these receptors are most prevalent—tamsulosin relaxes these muscles to improve urine flow and reduce BPH symptoms[2][7]. Its selectivity for alpha-1A over alpha-1B receptors results in fewer cardiovascular side effects compared to less selective agents[7]. Tamsulosin may also be used off-label for conditions like ureteral stones and prostatitis[5]. Developed by Astellas.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tamsulosin.